Impact of new systemic therapies on overall survival of patients with metastatic castration-resistant prostate cancer in a hospital-based registry
来源期刊：Prostate Cancer and Prostatic DiseasesDOI：10.1038/s41391-018-0121-2
The use of 68Ga-PET/CT PSMA to determine patterns of disease for biochemically recurrent prostate cancer following primary radiotherapy
来源期刊：Prostate Cancer and Prostatic DiseasesDOI：10.1038/s41391-019-0163-0
Hyperpolarized 13C-pyruvate MRI detects real-time metabolic flux in prostate cancer metastases to bone and liver: a clinical feasibility study
来源期刊：Prostate Cancer and Prostatic DiseasesDOI：10.1038/s41391-019-0180-z
Performance of [68Ga] Ga-PSMA 11 PET for detecting prostate cancer in the lymph nodes before salvage lymph node dissection: a systematic review and meta-analysis
来源期刊：Prostate Cancer and Prostatic DiseasesDOI：10.1038/s41391-019-0156-z
Prospective study to define the clinical utility and benefit of Decipher testing in men following prostatectomy
来源期刊：Prostate Cancer and Prostatic DiseasesDOI：10.1038/s41391-019-0185-7
Contemporary national trends in prostate cancer risk profile at diagnosis
来源期刊：Prostate Cancer and Prostatic DiseasesDOI：10.1038/s41391-019-0157-y
Effect of Dietary Omega-3 Fatty Acids on Castrate Resistant Prostate Cancer and Tumor Associated Macrophages
来源期刊：Prostate cancer and prostatic diseasesDOI：10.1038/s41391-019-0168-8
Association of Prostate Cancer SLCO Gene Expression with Gleason Grade and Alterations Following Androgen Deprivation Therapy
来源期刊：Prostate cancer and prostatic diseasesDOI：10.1038/s41391-019-0141-6
Prediction of extraprostatic extension by MRI tumor contact length: difference between anterior and posterior prostate cancer
来源期刊：Prostate Cancer and Prostatic DiseasesDOI：10.1038/s41391-019-0136-3
A review of prostate cancer treatment impact on the CNS and cognitive function
来源期刊：Prostate Cancer and Prostatic DiseasesDOI：10.1038/s41391-019-0195-5
Proton versus photon-based radiation therapy for prostate cancer: emerging evidence and considerations in the era of value-based cancer care
来源期刊：Prostate Cancer and Prostatic DiseasesDOI：10.1038/s41391-019-0140-7
Prospective examination of the changes in the urinary microbiome induced by transrectal biopsy of the prostate using 16S rRNA gene analysis
来源期刊：Prostate Cancer and Prostatic DiseasesDOI：10.1038/s41391-018-0120-3
Exploring the risk-reward balance in focal therapy for prostate cancer—a contribution to the debate
来源期刊：Prostate Cancer and Prostatic DiseasesDOI：10.1038/s41391-018-0125-y
Measuring the unmeasurable: automated bone scan index as a quantitative endpoint in prostate cancer clinical trials
来源期刊：Prostate Cancer and Prostatic DiseasesDOI：10.1038/s41391-019-0151-4
Lutetium-177 prostate-specific membrane antigen (PSMA) theranostics: practical nuances and intricacies
来源期刊：Prostate Cancer and Prostatic DiseasesDOI：10.1038/s41391-019-0174-x
Dietary inflammatory index (DII) and risk of prostate cancer in a case-control study among Black and White US Veteran men
来源期刊：Prostate cancer and prostatic diseasesDOI：10.1038/s41391-019-0143-4
Efficacy and safety of enucleation vs. resection of prostate for treatment of benign prostatic hyperplasia: a meta-analysis of randomized controlled trials
来源期刊：Prostate Cancer and Prostatic DiseasesDOI：10.1038/s41391-019-0135-4
Role of the DNA damage response in prostate cancer formation, progression and treatment
来源期刊：Prostate Cancer and Prostatic DiseasesDOI：10.1038/s41391-019-0153-2
Inherited risk assessment of prostate cancer: it takes three to do it right
来源期刊：Prostate Cancer and Prostatic DiseasesDOI：10.1038/s41391-019-0165-y
Validity of the National Death Index to Ascertain the Date and Cause of Death in Men Having Undergone Prostatectomy for Prostate Cancer
来源期刊：Prostate cancer and prostatic diseasesDOI：10.1038/s41391-019-0146-1
Diagnostic performance of 18F-PSMA-1007 PET/CT in biochemically relapsed patients with prostate cancer with PSA levels\u2009≤\u20092.0\u2009ng/ml
来源期刊：Prostate Cancer and Prostatic DiseasesDOI：10.1038/s41391-019-0194-6
Appetite-regulating hormones—leptin, adiponectin and ghrelin—and the development of prostate cancer: a systematic review and exploratory meta-analysis
来源期刊：Prostate Cancer and Prostatic DiseasesDOI：10.1038/s41391-019-0154-1
Assessment of body composition in the advanced stage of castration-resistant prostate cancer: special focus on sarcopenia
来源期刊：Prostate Cancer and Prostatic DiseasesDOI：10.1038/s41391-019-0186-6
Prolonged PSA stabilization and overall survival following sipuleucel-T monotherapy in metastatic castration-resistant prostate cancer patients
来源期刊：Prostate Cancer and Prostatic DiseasesDOI：10.1038/s41391-019-0144-3
A polymeric paste-drug formulation for intratumoral treatment of prostate cancer
来源期刊：Prostate Cancer and Prostatic DiseasesDOI：10.1038/s41391-019-0190-x
Adiponectin: the “unusual suspect” between insulin resistance and cancer?
来源期刊：Prostate Cancer and Prostatic DiseasesDOI：10.1038/s41391-019-0142-5
Prostate Cancer and Prostatic Diseases Best of Asia, 2019: challenges and opportunities
来源期刊：Prostate Cancer and Prostatic DiseasesDOI：10.1038/s41391-019-0193-7
Validation of a genomic classifier for prediction of metastasis and prostate cancer-specific mortality in African-American men following radical prostatectomy in an equal access healthcare setting
来源期刊：Prostate Cancer and Prostatic DiseasesDOI：10.1038/s41391-019-0197-3
A predictive model based on biparametric magnetic resonance imaging and clinical parameters for improved risk assessment and selection of biopsy-naïve men for prostate biopsies
来源期刊：Prostate Cancer and Prostatic DiseasesDOI：10.1038/s41391-019-0149-y
The development and comparative effectiveness of a patient-centered prostate biopsy report: a prospective, randomized study
来源期刊：Prostate Cancer and Prostatic DiseasesDOI：10.1038/s41391-019-0169-7
Preoperative PI-RADS Version 2 scores helps improve accuracy of clinical nomograms for predicting pelvic lymph node metastasis at radical prostatectomy
来源期刊：Prostate Cancer and Prostatic DiseasesDOI：10.1038/s41391-019-0164-z
Decipher identifies men with otherwise clinically favorable-intermediate risk disease who may not be good candidates for active surveillance
来源期刊：Prostate Cancer and Prostatic DiseasesDOI：10.1038/s41391-019-0167-9
Efficacy and safety of periprostatic nerve block combined with perineal subcutaneous anaesthesia and intrarectal lidocaine gel in transrectal ultrasound guided transperineal prostate biopsy: A Prospective Randomised Controlled Trial
来源期刊：Prostate Cancer and Prostatic DiseasesDOI：10.1038/s41391-019-0155-0
Cost-effectiveness analysis of Abiraterone Acetate versus Docetaxel in the management of metastatic castration-sensitive prostate cancer: Hong Kong’s perspective
来源期刊：Prostate Cancer and Prostatic DiseasesDOI：10.1038/s41391-019-0161-2
Temporal trends and social barriers for inpatient palliative care delivery in metastatic prostate cancer patients receiving critical care therapies
来源期刊：Prostate Cancer and Prostatic DiseasesDOI：10.1038/s41391-019-0183-9
Tobacco smoking and death from prostate cancer in US veterans
来源期刊：Prostate Cancer and Prostatic DiseasesDOI：10.1038/s41391-019-0178-6
Germline polymorphisms associated with impaired survival outcomes and somatic tumor alterations in advanced prostate cancer
来源期刊：Prostate Cancer and Prostatic DiseasesDOI：10.1038/s41391-019-0188-4
Stroke and thromboembolic events in men with prostate cancer treated with definitive radiation therapy with or without androgen deprivation therapy
来源期刊：Prostate Cancer and Prostatic DiseasesDOI：10.1038/s41391-019-0150-5
United States trends in active surveillance or watchful waiting across patient socioeconomic status from 2010 to 2015
来源期刊：Prostate Cancer and Prostatic DiseasesDOI：10.1038/s41391-019-0175-9
Allopurinol and the risk of prostate cancer in a Finnish population-based cohort
来源期刊：Prostate Cancer and Prostatic DiseasesDOI：10.1038/s41391-019-0129-2
Correction: Metabolic syndrome increases the risk of upgrading and upstaging in patients with prostate cancer on biopsy: a radical prostatectomy multicenter cohort study
来源期刊：Prostate Cancer and Prostatic DiseasesDOI：10.1038/s41391-019-0132-7
How can mpMRI help surgical planning in high risk prostate cancer?
来源期刊：Prostate Cancer and Prostatic DiseasesDOI：10.1038/s41391-019-0192-8
Prostate cancer characteristics and cancer-specific mortality of Native American patients
来源期刊：Prostate Cancer and Prostatic DiseasesDOI：10.1038/s41391-019-0184-8
Correction: Predictors of fluoroquinolone-resistant bacteria in the rectal vault of men undergoing prostate biopsy
来源期刊：Prostate Cancer and Prostatic DiseasesDOI：10.1038/s41391-019-0133-6
Letter to the Editor: “Characterizing the learning curve of the MRI–US fusion prostate biopsies”
来源期刊：Prostate Cancer and Prostatic DiseasesDOI：10.1038/s41391-019-0148-z
Assessing the relationship between statin use and oncologic outcomes among men electing active surveillance for localized prostate cancer
来源期刊：Prostate Cancer and Prostatic DiseasesDOI：10.1038/s41391-019-0147-0
Correction to: Role of the DNA damage response in prostate cancer formation, progression and treatment
来源期刊：Prostate Cancer and Prostatic DiseasesDOI：10.1038/s41391-019-0162-1
Feasibility and continence outcomes of extended prostatic urethral preservation during robot-assisted radical prostatectomy
来源期刊：Prostate Cancer and Prostatic DiseasesDOI：10.1038/s41391-019-0173-y
Correction: Confirmatory multiparametric magnetic resonance imaging at recruitment confers prolonged stay in active surveillance and decreases the rate of upgrading at follow-up
来源期刊：Prostate Cancer and Prostatic DiseasesDOI：10.1038/s41391-019-0198-2
Germline genetic variation in prostate susceptibility does not predict outcomes in the chemoprevention trials PCPT and SELECT
来源期刊：Prostate Cancer and Prostatic DiseasesDOI：10.1038/s41391-019-0181-y
投稿咨询
加急服务
论文发表
2-4个月录用
7500+文章录用
不成功可退款
